{"success":true,"data":{"pressRelease":{"id":"169415","rtpr_id":"nPn3PH8Bpa-20261014","ticker":"ACB","exchange":"NASDAQ","all_tickers":["ACB"],"title":"Aurora Cannabis Reaffirms Recommendation to Shareholders: REJECT Curaleaf's Revised Hostile Bid; Preserve Opportunities for Future Upside","author":"PR Newswire","published_at":"2026-10-14T19:49:11.071Z","article_body":"Aurora Cannabis Reaffirms Recommendation to Shareholders: REJECT Curaleaf's Revised Hostile Bid; Preserve Opportunities for Future Upside\nPR Newswire\n\nEDMONTON, AB, Oct. 14, 2026\n\nNASDAQ | TSX: ACB\n\n * Revised Hostile Bid continues to significantly undervalue Aurora; fails to\naddress concerns previously raised by the Board.\n * Aurora's Special Committee is actively exploring strategic alternatives to\nmaximize value for Aurora shareholders.\n * Shareholders are advised to REJECT the revised Hostile Bid and TAKE NO\nACTION at this time before other strategic alternatives may emerge.\n * Questions about the Hostile Bid or would like to stay informed? Contact Kingsdale\nAdvisors toll-free at 1-800-749-9052 within North America, call or text 416-623-4172 or\nemail\ncontactus@kingsdaleadvisors.com (mailto:contactus@kingsdaleadvisors.com)\n.\nEDMONTON, AB, Oct. 14, 2026 /PRNewswire/ -- Aurora Cannabis Inc. (\"Aurora\" or\nthe \"Company\") (TSX: ACB) (NASDAQ: ACB), the Canadian-based leading global\nmedical cannabis company, today reconfirms that the Board of Directors (the\n\"Board\"), on the unanimous recommendation of a special committee of\nindependent directors (the \"Special Committee\"), unanimously recommends that\nshareholders REJECT the hostile offer by Curaleaf Holdings, Inc. (\"Curaleaf\")\n(TSX: CURA) (OTCQX: CURLF) for all of the issued and outstanding common shares\nof the Company, as revised in the Notice of Variation, Change and Extension\nfiled by Curaleaf on October 6, 2026 (the \"Hostile Bid\").\n\n\"Curaleaf's revised offer still does not reflect the value of the company\nAurora shareholders own today. Aurora is debt-free with a strong cash\nposition, and we believe the revised Hostile Bid continues to ask shareholders\nto give up that strength, and their future upside, at a discount,\" said Miguel\nMartin, Executive Chairman and CEO of Aurora.\n\n\"At the same time, our Special Committee is carefully evaluating strategic\nalternatives with the goal of delivering greater value for Aurora\nshareholders. Curaleaf's offer remains open until December 4, 2026, so we\nbelieve shareholders gain nothing by tendering now, and tendering early could\nundermine the opportunity for a superior outcome. We urge shareholders to keep\ntheir options open, reject the revised Hostile Bid and take no action until\nthey can consider all the alternatives available to them,\" concluded Mr.\nMartin.\n\nThe Board's determination follows careful consideration of, among other\nthings, advice from its financial and legal advisors, including an updated\ninadequacy opinion from its financial advisor, and the unanimous\nrecommendation of the Special Committee. To reject the revised Hostile Bid,\nsimply TAKE NO ACTION. Shareholders who have tendered their Aurora shares and\nwish to withdraw, are advised to contact their broker or contact Kingsdale\nAdvisors to assist with this process.\n\nA Notice of Change to Directors' Circular (the \"Notice of Change\") providing\nthe full details concerning the Board's recommendation, including the reasons\nto REJECT the revised Hostile Bid and additional details in respect\nof the ongoing strategic alternatives process, will be made available on the\nCompany's special website at www.ProtectAurora.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4798213-1&h=1673288480&u=http%3A%2F%2Fwww.protectaurora.com%2F&a=www.ProtectAurora.com)\n, on SEDAR+ at www.sedarplus.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4798213-1&h=2884712074&u=https%3A%2F%2Fwww.sedarplus.com&a=www.sedarplus.com)\n and on EDGAR at www.sec.gov\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4798213-1&h=2811558845&u=https%3A%2F%2Fwww.sec.gov&a=www.sec.gov)\n. The principal reasons for the Board's recommendation to reject the revised\nHostile Bid will be detailed in the Notice of Change and include:\n\n * The revised Hostile Bid remains inadequate and significantly undervalues\nAurora on several measures. The Board and Special Committee have received an\nupdated fairness opinion from their financial advisor confirming that the\nrevised consideration is inadequate, from a financial point of view, to Aurora\nshareholders.\n * Curaleaf continues to propose to use Aurora Shareholders' own cash to acquire\ncontrol of Aurora without paying fairly. A significant portion of the cash\nconsideration would, in effect, be funded by the Aurora Shareholder's own cash\nthrough Aurora's balance sheet.\n * Aurora Shareholders bear the risk. The increase in consideration consists\nprincipally of Curaleaf shares at an inflated valuation; Aurora shareholders\nwould remain fully exposed to any decline in the Curaleaf share price.\n * The Hostile Bid remains opportunistic. It seeks to acquire Aurora's assets at\na discount and does not reflect the longer-term earning power of Aurora's\nglobal business.\n * Curaleaf has not adequately supported its estimated synergies. Even if the\nsynergies were realized, substantially all of the benefit would accrue to\nCuraleaf's existing shareholders and not Aurora shareholders.\n * Superior proposals or other alternatives may emerge from Aurora's ongoing\nstrategic review process. Aurora shareholders are encouraged to wait for the\nresults of that process. Tendering into the Hostile Bid could negatively\naffect the possibility of a superior alternative being available for Aurora\nshareholders to consider.\nUpdate on Strategic Alternatives Process\n\nThe Special Committee, with the assistance of its and the Company's financial\nand legal advisors, is actively exploring a range of alternatives to the\nrevised Hostile Bid that may offer shareholders greater value than the revised\nHostile Bid. These alternatives include, among other things, a possible\ntransaction with one or more third parties or remaining independent and\npursuing Aurora's existing strategy as a stand-alone entity.\n\nThe Special Committee, through the Company's financial advisor, has solicited\na number of parties to ascertain their interest in Aurora. Aurora has entered\ninto confidentiality and standstill agreements with multiple parties, each of\nwhom have been examining information relating to Aurora. Aurora has had\nnumerous discussions with these parties. As this process is ongoing, it is\nnot possible at this time to predict with certainty what alternatives (if any)\nmay emerge from this process. There can be no assurance that the process will\nresult in a transaction. However, shareholders should not tender their shares\nuntil the process is completed.\n\nThe Board and the Special Committee believe that it is in the best interests\nof Aurora and its shareholders for there to be sufficient time to permit\nstrategic alternatives that may be available to Aurora to emerge, and for the\nSpecial Committee to review and evaluate such potential alternatives. After\nthe Special Committee and the Board have had the opportunity to explore,\npursue and evaluate alternatives, the Board intends to provide a further\nrecommendation to shareholders. Tendering into the revised Hostile Bid\nprematurely could negatively affect the possibility of a superior alternative\nbeing available for shareholders to consider.\n\nShareholder Assistance\n\nAurora shareholders with questions about the revised\nHostile Bid or who would like to stay informed may contact Kingsdale\nAdvisors, the Company's strategic advisor and information agent:\n\n * Toll-Free (within North America): 1-800-749-9052\n * Call or Text: 416-623-4172\n * Email:\ncontactus@kingsdaleadvisors.com (mailto:contactus@kingsdaleadvisors.com)\n * Visit\nwww.ProtectAurora.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4798213-1&h=84078155&u=https%3A%2F%2Fwww.protectaurora.com%2F&a=www.ProtectAurora.com)\nAbout Aurora Cannabis\n\nAurora is a global leader in medical cannabis, dedicated to improving lives\nthrough scientific expertise, proven performance, and a deep commitment to\npatient care. Aurora serves medical markets across Canada, Europe, Australia,\nand New Zealand with a portfolio of trusted, leading brands including\nAurora(®), MedReleaf(®), Pedanios(®), IndiMed(™), San Raf(®), and\nWhistler Medical Marijuana Corporation(®). With world-class GMP-certified\nmanufacturing facilities in Canada and Germany, and a team of industry-leading\nprofessionals, Aurora continues to expand its global footprint and deliver\nconsistent, high-quality cannabis products with the purpose of Opening the\nWorld to Cannabis(™).\n\nLearn more at www.auroramj.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4798213-1&h=2619940402&u=http%3A%2F%2Fwww.auroramj.com%2F&a=www.auroramj.com)\n and follow us on X\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4798213-1&h=132600378&u=https%3A%2F%2Fx.com%2FAurora_MMJ&a=X)\n and LinkedIn.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4798213-1&h=3922987246&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Faurora-cannabis-inc-%2Fposts%2F&a=LinkedIn.)\n\nAurora's common shares trade on the NASDAQ and TSX under the symbol \"ACB\".\n\nAurora has filed a Solicitation/Recommendation Statement on Schedule 14D-9F\nwith the U.S. Securities and Exchange Commission (the \"SEC\"), which includes a\nDirectors' Circular, dated September 1, 2026, as amended by the Notice of\nChange. Investors are urged to read this document and any other relevant\ndocuments filed with the SEC, as well as any amendments or supplements to\nthese documents, when they become available, before making any investment\ndecision with respect to the Hostile Bid. The Hostile Bid is made for the\nsecurities of a Canadian issuer and while the Hostile Bid is subject to\ndisclosure requirements of Canada, investors should be aware that these\nrequirements are different from those of the United States. The enforcement by\ninvestors of civil liabilities under the U.S. federal securities laws may be\naffected adversely by the fact that the issuer is located in Canada, and that\nsome or all of its officers and directors are residents of Canada.\n\nForward-Looking Statements\n\nThis news release includes statements containing certain \"forward-looking\ninformation\" within the meaning of applicable securities laws\n(\"forward-looking statements\"). Forward-looking statements are frequently\ncharacterized by words such as \"plan\", \"continue\", \"expect\", \"project\",\n\"intend\", \"believe\", \"anticipate\", \"estimate\", \"may\", \"will\", \"potential\",\n\"proposed\" and other similar words, or statements that certain events or\nconditions \"may\" or \"will\" occur. Forward-looking statements made in this news\nrelease include, but are not limited to, statements and information regarding\nthe Company's strategy and opportunities for creating and increasing long-term\nvalue for shareholders, the Special Committee's strategic alternatives process\nand the potential outcomes thereof, and expected impacts for Aurora\nshareholders.\n\nThese forward-looking statements are only predictions. Forward-looking\ninformation or statements contained in this news release have been developed\nbased on the Company and its management's good faith assumptions relating to\nthe financial, market, regulatory and other relevant environments that will\nexist and affect the Company's business and operations in the future.\nForward-looking information and statements are not a guarantee of future\nperformance and are based upon a number of estimates and assumptions of\nmanagement at the date the statements are made including, among other things,\nassumptions about: development costs remaining consistent with budgets; the\nability to manage anticipated and unanticipated costs; access to favorable\nequity and debt capital markets; the ability to raise sufficient capital to\nadvance the business of the Company; favorable operating and economic\nconditions; political and regulatory stability; obtaining and maintaining all\nrequired licenses and permits; receipt of governmental approvals and permits;\nsustained labour stability; stability in financial and capital goods markets;\nfavorable production levels and costs from the Company's operations; the\npricing of various cannabis products; the level of demand for cannabis\nproducts; the availability of third-party service providers and other inputs\nfor the Company's operations; and the Company's ability to conduct operations\nin a safe, efficient, and effective manner. The Company does not give any\nassurance that the assumptions on which forward-looking information or\nstatements are based will prove to be correct, or that the Company's business\nor operations will not be affected in any material manner by these or other\nfactors not foreseen or foreseeable by the Company or management or beyond the\nCompany's control. Such forward-looking statements are estimates reflecting\nthe Company's best judgment based upon current information and involve a\nnumber of risks and uncertainties, and there can be no assurance that other\nfactors will not affect the accuracy of such forward-looking statements. These\nrisks include, but are not limited to, the ability to retain key personnel,\nthe ability to continue investing in infrastructure to support growth, the\nability to obtain financing on acceptable terms, the continued quality of our\nproducts, customer experience and retention, the development of third party\ngovernment and non-government consumer sales channels, management's estimates\nof consumer demand in Canada and in jurisdictions where the Company exports,\nexpectations of future results and expenses, the availability of additional\ncapital to complete construction projects and facilities improvements, the\nrisk of successful integration of acquired business and operations,\nmanagement's estimation that SG&A will grow only in proportion to revenue\ngrowth, the ability to expand and maintain distribution capabilities, the\nimpact of competition, the general impact of financial market conditions, the\nyield from cannabis growing operations, product demand, changes in prices of\nrequired commodities, competition, and the possibility for changes in laws,\nrules, and regulations in the industry, epidemics, pandemics or other public\nhealth crisis, and other risks as set out under the heading \"Risk Factors\" in\nthe Company's annual information form dated June 10, 2026 (the \"AIF\") and\nfiled with Canadian securities regulators available on the Company's issuer\nprofile on SEDAR+ at www.sedarplus.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4798213-1&h=338627363&u=http%3A%2F%2Fwww.sedarplus.com%2F&a=www.sedarplus.com)\nand filed with and available on the SEC's website at www.sec.gov.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4798213-1&h=3502939855&u=http%3A%2F%2Fwww.sec.gov%2F&a=www.sec.gov.)\nThe Company cautions that the list of risks, uncertainties and other factors\ndescribed in the AIF is not exhaustive and other factors could also adversely\naffect its results. Readers are urged to consider the risks, uncertainties and\nassumptions carefully in evaluating the forward-looking statements and are\ncautioned not to place undue reliance on such information. The Company is\nunder no obligation, and expressly disclaims any intention or obligation, to\nupdate or revise any forward-looking statements, whether as a result of new\ninformation, future events or otherwise, except as expressly required by\napplicable securities laws.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-reaffirms-recommendation-to-shareholders-reject-curaleafs-revised-hostile-bid-preserve-opportunities-for-future-upside-302909066.html\n(https://www.prnewswire.com/news-releases/aurora-cannabis-reaffirms-recommendation-to-shareholders-reject-curaleafs-revised-hostile-bid-preserve-opportunities-for-future-upside-302909066.html)\n\nSOURCE Aurora Cannabis Inc.\n\n\n\nFor Media: Michelle Lefler, VP, Communications & PR, media@auroramj.com; For Investors: ICR, Inc., Investor Relations, aurora@icrinc.com\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1136461/Aurora-Cannabis-Inc-Aurora-Cannabis-Reaffirms-Recommendation-to.jpg?id=OA3019552\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn3PH8Bpa-20261014","title":"Aurora Cannabis Reaffirms Recommendation to Shareholders: REJECT Curaleaf's Revised Hostile Bid; Preserve Opportunities for Future Upside","author":"PR Newswire","ticker":"ACB","created":"2026-10-14T19:49:11.071Z","tickers":["ACB"],"exchange":"NASDAQ","article_body":"Aurora Cannabis Reaffirms Recommendation to Shareholders: REJECT Curaleaf's Revised Hostile Bid; Preserve Opportunities for Future Upside\nPR Newswire\n\nEDMONTON, AB, Oct. 14, 2026\n\nNASDAQ | TSX: ACB\n\n * Revised Hostile Bid continues to significantly undervalue Aurora; fails to\naddress concerns previously raised by the Board.\n * Aurora's Special Committee is actively exploring strategic alternatives to\nmaximize value for Aurora shareholders.\n * Shareholders are advised to REJECT the revised Hostile Bid and TAKE NO\nACTION at this time before other strategic alternatives may emerge.\n * Questions about the Hostile Bid or would like to stay informed? Contact Kingsdale\nAdvisors toll-free at 1-800-749-9052 within North America, call or text 416-623-4172 or\nemail\ncontactus@kingsdaleadvisors.com (mailto:contactus@kingsdaleadvisors.com)\n.\nEDMONTON, AB, Oct. 14, 2026 /PRNewswire/ -- Aurora Cannabis Inc. (\"Aurora\" or\nthe \"Company\") (TSX: ACB) (NASDAQ: ACB), the Canadian-based leading global\nmedical cannabis company, today reconfirms that the Board of Directors (the\n\"Board\"), on the unanimous recommendation of a special committee of\nindependent directors (the \"Special Committee\"), unanimously recommends that\nshareholders REJECT the hostile offer by Curaleaf Holdings, Inc. (\"Curaleaf\")\n(TSX: CURA) (OTCQX: CURLF) for all of the issued and outstanding common shares\nof the Company, as revised in the Notice of Variation, Change and Extension\nfiled by Curaleaf on October 6, 2026 (the \"Hostile Bid\").\n\n\"Curaleaf's revised offer still does not reflect the value of the company\nAurora shareholders own today. Aurora is debt-free with a strong cash\nposition, and we believe the revised Hostile Bid continues to ask shareholders\nto give up that strength, and their future upside, at a discount,\" said Miguel\nMartin, Executive Chairman and CEO of Aurora.\n\n\"At the same time, our Special Committee is carefully evaluating strategic\nalternatives with the goal of delivering greater value for Aurora\nshareholders. Curaleaf's offer remains open until December 4, 2026, so we\nbelieve shareholders gain nothing by tendering now, and tendering early could\nundermine the opportunity for a superior outcome. We urge shareholders to keep\ntheir options open, reject the revised Hostile Bid and take no action until\nthey can consider all the alternatives available to them,\" concluded Mr.\nMartin.\n\nThe Board's determination follows careful consideration of, among other\nthings, advice from its financial and legal advisors, including an updated\ninadequacy opinion from its financial advisor, and the unanimous\nrecommendation of the Special Committee. To reject the revised Hostile Bid,\nsimply TAKE NO ACTION. Shareholders who have tendered their Aurora shares and\nwish to withdraw, are advised to contact their broker or contact Kingsdale\nAdvisors to assist with this process.\n\nA Notice of Change to Directors' Circular (the \"Notice of Change\") providing\nthe full details concerning the Board's recommendation, including the reasons\nto REJECT the revised Hostile Bid and additional details in respect\nof the ongoing strategic alternatives process, will be made available on the\nCompany's special website at www.ProtectAurora.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4798213-1&h=1673288480&u=http%3A%2F%2Fwww.protectaurora.com%2F&a=www.ProtectAurora.com)\n, on SEDAR+ at www.sedarplus.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4798213-1&h=2884712074&u=https%3A%2F%2Fwww.sedarplus.com&a=www.sedarplus.com)\n and on EDGAR at www.sec.gov\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4798213-1&h=2811558845&u=https%3A%2F%2Fwww.sec.gov&a=www.sec.gov)\n. The principal reasons for the Board's recommendation to reject the revised\nHostile Bid will be detailed in the Notice of Change and include:\n\n * The revised Hostile Bid remains inadequate and significantly undervalues\nAurora on several measures. The Board and Special Committee have received an\nupdated fairness opinion from their financial advisor confirming that the\nrevised consideration is inadequate, from a financial point of view, to Aurora\nshareholders.\n * Curaleaf continues to propose to use Aurora Shareholders' own cash to acquire\ncontrol of Aurora without paying fairly. A significant portion of the cash\nconsideration would, in effect, be funded by the Aurora Shareholder's own cash\nthrough Aurora's balance sheet.\n * Aurora Shareholders bear the risk. The increase in consideration consists\nprincipally of Curaleaf shares at an inflated valuation; Aurora shareholders\nwould remain fully exposed to any decline in the Curaleaf share price.\n * The Hostile Bid remains opportunistic. It seeks to acquire Aurora's assets at\na discount and does not reflect the longer-term earning power of Aurora's\nglobal business.\n * Curaleaf has not adequately supported its estimated synergies. Even if the\nsynergies were realized, substantially all of the benefit would accrue to\nCuraleaf's existing shareholders and not Aurora shareholders.\n * Superior proposals or other alternatives may emerge from Aurora's ongoing\nstrategic review process. Aurora shareholders are encouraged to wait for the\nresults of that process. Tendering into the Hostile Bid could negatively\naffect the possibility of a superior alternative being available for Aurora\nshareholders to consider.\nUpdate on Strategic Alternatives Process\n\nThe Special Committee, with the assistance of its and the Company's financial\nand legal advisors, is actively exploring a range of alternatives to the\nrevised Hostile Bid that may offer shareholders greater value than the revised\nHostile Bid. These alternatives include, among other things, a possible\ntransaction with one or more third parties or remaining independent and\npursuing Aurora's existing strategy as a stand-alone entity.\n\nThe Special Committee, through the Company's financial advisor, has solicited\na number of parties to ascertain their interest in Aurora. Aurora has entered\ninto confidentiality and standstill agreements with multiple parties, each of\nwhom have been examining information relating to Aurora. Aurora has had\nnumerous discussions with these parties. As this process is ongoing, it is\nnot possible at this time to predict with certainty what alternatives (if any)\nmay emerge from this process. There can be no assurance that the process will\nresult in a transaction. However, shareholders should not tender their shares\nuntil the process is completed.\n\nThe Board and the Special Committee believe that it is in the best interests\nof Aurora and its shareholders for there to be sufficient time to permit\nstrategic alternatives that may be available to Aurora to emerge, and for the\nSpecial Committee to review and evaluate such potential alternatives. After\nthe Special Committee and the Board have had the opportunity to explore,\npursue and evaluate alternatives, the Board intends to provide a further\nrecommendation to shareholders. Tendering into the revised Hostile Bid\nprematurely could negatively affect the possibility of a superior alternative\nbeing available for shareholders to consider.\n\nShareholder Assistance\n\nAurora shareholders with questions about the revised\nHostile Bid or who would like to stay informed may contact Kingsdale\nAdvisors, the Company's strategic advisor and information agent:\n\n * Toll-Free (within North America): 1-800-749-9052\n * Call or Text: 416-623-4172\n * Email:\ncontactus@kingsdaleadvisors.com (mailto:contactus@kingsdaleadvisors.com)\n * Visit\nwww.ProtectAurora.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4798213-1&h=84078155&u=https%3A%2F%2Fwww.protectaurora.com%2F&a=www.ProtectAurora.com)\nAbout Aurora Cannabis\n\nAurora is a global leader in medical cannabis, dedicated to improving lives\nthrough scientific expertise, proven performance, and a deep commitment to\npatient care. Aurora serves medical markets across Canada, Europe, Australia,\nand New Zealand with a portfolio of trusted, leading brands including\nAurora(®), MedReleaf(®), Pedanios(®), IndiMed(™), San Raf(®), and\nWhistler Medical Marijuana Corporation(®). With world-class GMP-certified\nmanufacturing facilities in Canada and Germany, and a team of industry-leading\nprofessionals, Aurora continues to expand its global footprint and deliver\nconsistent, high-quality cannabis products with the purpose of Opening the\nWorld to Cannabis(™).\n\nLearn more at www.auroramj.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4798213-1&h=2619940402&u=http%3A%2F%2Fwww.auroramj.com%2F&a=www.auroramj.com)\n and follow us on X\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4798213-1&h=132600378&u=https%3A%2F%2Fx.com%2FAurora_MMJ&a=X)\n and LinkedIn.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4798213-1&h=3922987246&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Faurora-cannabis-inc-%2Fposts%2F&a=LinkedIn.)\n\nAurora's common shares trade on the NASDAQ and TSX under the symbol \"ACB\".\n\nAurora has filed a Solicitation/Recommendation Statement on Schedule 14D-9F\nwith the U.S. Securities and Exchange Commission (the \"SEC\"), which includes a\nDirectors' Circular, dated September 1, 2026, as amended by the Notice of\nChange. Investors are urged to read this document and any other relevant\ndocuments filed with the SEC, as well as any amendments or supplements to\nthese documents, when they become available, before making any investment\ndecision with respect to the Hostile Bid. The Hostile Bid is made for the\nsecurities of a Canadian issuer and while the Hostile Bid is subject to\ndisclosure requirements of Canada, investors should be aware that these\nrequirements are different from those of the United States. The enforcement by\ninvestors of civil liabilities under the U.S. federal securities laws may be\naffected adversely by the fact that the issuer is located in Canada, and that\nsome or all of its officers and directors are residents of Canada.\n\nForward-Looking Statements\n\nThis news release includes statements containing certain \"forward-looking\ninformation\" within the meaning of applicable securities laws\n(\"forward-looking statements\"). Forward-looking statements are frequently\ncharacterized by words such as \"plan\", \"continue\", \"expect\", \"project\",\n\"intend\", \"believe\", \"anticipate\", \"estimate\", \"may\", \"will\", \"potential\",\n\"proposed\" and other similar words, or statements that certain events or\nconditions \"may\" or \"will\" occur. Forward-looking statements made in this news\nrelease include, but are not limited to, statements and information regarding\nthe Company's strategy and opportunities for creating and increasing long-term\nvalue for shareholders, the Special Committee's strategic alternatives process\nand the potential outcomes thereof, and expected impacts for Aurora\nshareholders.\n\nThese forward-looking statements are only predictions. Forward-looking\ninformation or statements contained in this news release have been developed\nbased on the Company and its management's good faith assumptions relating to\nthe financial, market, regulatory and other relevant environments that will\nexist and affect the Company's business and operations in the future.\nForward-looking information and statements are not a guarantee of future\nperformance and are based upon a number of estimates and assumptions of\nmanagement at the date the statements are made including, among other things,\nassumptions about: development costs remaining consistent with budgets; the\nability to manage anticipated and unanticipated costs; access to favorable\nequity and debt capital markets; the ability to raise sufficient capital to\nadvance the business of the Company; favorable operating and economic\nconditions; political and regulatory stability; obtaining and maintaining all\nrequired licenses and permits; receipt of governmental approvals and permits;\nsustained labour stability; stability in financial and capital goods markets;\nfavorable production levels and costs from the Company's operations; the\npricing of various cannabis products; the level of demand for cannabis\nproducts; the availability of third-party service providers and other inputs\nfor the Company's operations; and the Company's ability to conduct operations\nin a safe, efficient, and effective manner. The Company does not give any\nassurance that the assumptions on which forward-looking information or\nstatements are based will prove to be correct, or that the Company's business\nor operations will not be affected in any material manner by these or other\nfactors not foreseen or foreseeable by the Company or management or beyond the\nCompany's control. Such forward-looking statements are estimates reflecting\nthe Company's best judgment based upon current information and involve a\nnumber of risks and uncertainties, and there can be no assurance that other\nfactors will not affect the accuracy of such forward-looking statements. These\nrisks include, but are not limited to, the ability to retain key personnel,\nthe ability to continue investing in infrastructure to support growth, the\nability to obtain financing on acceptable terms, the continued quality of our\nproducts, customer experience and retention, the development of third party\ngovernment and non-government consumer sales channels, management's estimates\nof consumer demand in Canada and in jurisdictions where the Company exports,\nexpectations of future results and expenses, the availability of additional\ncapital to complete construction projects and facilities improvements, the\nrisk of successful integration of acquired business and operations,\nmanagement's estimation that SG&A will grow only in proportion to revenue\ngrowth, the ability to expand and maintain distribution capabilities, the\nimpact of competition, the general impact of financial market conditions, the\nyield from cannabis growing operations, product demand, changes in prices of\nrequired commodities, competition, and the possibility for changes in laws,\nrules, and regulations in the industry, epidemics, pandemics or other public\nhealth crisis, and other risks as set out under the heading \"Risk Factors\" in\nthe Company's annual information form dated June 10, 2026 (the \"AIF\") and\nfiled with Canadian securities regulators available on the Company's issuer\nprofile on SEDAR+ at www.sedarplus.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4798213-1&h=338627363&u=http%3A%2F%2Fwww.sedarplus.com%2F&a=www.sedarplus.com)\nand filed with and available on the SEC's website at www.sec.gov.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4798213-1&h=3502939855&u=http%3A%2F%2Fwww.sec.gov%2F&a=www.sec.gov.)\nThe Company cautions that the list of risks, uncertainties and other factors\ndescribed in the AIF is not exhaustive and other factors could also adversely\naffect its results. Readers are urged to consider the risks, uncertainties and\nassumptions carefully in evaluating the forward-looking statements and are\ncautioned not to place undue reliance on such information. The Company is\nunder no obligation, and expressly disclaims any intention or obligation, to\nupdate or revise any forward-looking statements, whether as a result of new\ninformation, future events or otherwise, except as expressly required by\napplicable securities laws.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-reaffirms-recommendation-to-shareholders-reject-curaleafs-revised-hostile-bid-preserve-opportunities-for-future-upside-302909066.html\n(https://www.prnewswire.com/news-releases/aurora-cannabis-reaffirms-recommendation-to-shareholders-reject-curaleafs-revised-hostile-bid-preserve-opportunities-for-future-upside-302909066.html)\n\nSOURCE Aurora Cannabis Inc.\n\n\n\nFor Media: Michelle Lefler, VP, Communications & PR, media@auroramj.com; For Investors: ICR, Inc., Investor Relations, aurora@icrinc.com\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1136461/Aurora-Cannabis-Inc-Aurora-Cannabis-Reaffirms-Recommendation-to.jpg?id=OA3019552\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-14T19:49:11.105698706Z","server_sent_at_ms":1792007351105},"received_at":"2026-10-14T19:49:11.262Z","source_url":"https://www.prnewswire.com/news-releases/aurora-cannabis-reaffirms-recommendation-to-shareholders-reject-curaleafs-revised-hostile-bid-preserve-opportunities-for-future-upside-302909066.html"},"analysis":{"id":"157652","press_release_id":"169415","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["hostile bid unresolved with December 4, 2026 expiration overhanging the stock","consideration increase is principally Curaleaf shares, exposing ACB holders to CURA share-price risk","no assurance the strategic-alternatives process will produce a superior transaction","financial advisor fairness opinion deems revised bid consideration inadequate"],"eventType":"m_and_a","narrative":"Aurora Cannabis' board, on the unanimous recommendation of its Special Committee, again advised shareholders to reject Curaleaf's revised hostile bid for all outstanding ACB shares.\n\nThe board says the revised offer significantly undervalues Aurora, which is debt-free with a strong cash position, and that the cash consideration would effectively be funded by Aurora shareholders' own balance-sheet cash.\n\nAurora's Special Committee is actively exploring strategic alternatives, having signed confidentiality and standstill agreements with multiple interested parties; Curaleaf's bid remains open until December 4, 2026.\n\nShareholders are advised to take no action, as tendering early could undermine the potential for a superior outcome from the strategic review.","sentiment":"neutral","agentHooks":{"shouldPost":true,"suggestedAngle":"Aurora board rejects Curaleaf's revised hostile bid and points to live strategic-alternatives talks with multiple parties -- watch for a topping bid or CURA response into the Dec 4 deadline."},"keyFigures":{"customDimensions":{"bid_status":"revised hostile bid rejected; strategic alternatives process ongoing","bid_expiration":"December 4, 2026"}},"quotedText":"Aurora is debt-free with a strong cash position, and we believe the revised Hostile Bid continues to ask shareholders to give up that strength, and their future upside, at a discount","namedEntities":{"people":[{"name":"Miguel Martin","role":"Executive Chairman and CEO of Aurora Cannabis"},{"name":"Michelle Lefler","role":"VP, Communications & PR, Aurora Cannabis"}],"products":["Aurora","MedReleaf","Pedanios","IndiMed","San Raf","Whistler Medical Marijuana Corporation"],"companies":[{"name":"Aurora Cannabis Inc.","ticker":"ACB","relationship":"filer / bid target"},{"name":"Curaleaf Holdings, Inc.","ticker":"CURA","relationship":"hostile bidder"},{"name":"Kingsdale Advisors","relationship":"strategic advisor and information agent"},{"name":"ICR, Inc.","relationship":"investor relations"}],"dollarAmounts":[]},"materialImpact":{"score":4,"reasoning":"Ongoing hostile takeover battle: Aurora's board unanimously rejects Curaleaf's revised hostile bid and is actively running a strategic-alternatives process with multiple parties under confidentiality agreements. Outcome will directly determine ACB shareholder value, though no new deal terms or figures are disclosed."},"tickerRelevance":{"others":[{"ticker":"CURA","relevance":"hostile bidder / acquirer"},{"ticker":"CURLF","relevance":"hostile bidder (OTCQX listing)"}],"primary":"ACB"},"globalImportance":55,"audienceRelevance":60,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap cannabis, well-known retail name","eventGravity":"hostile M&A defense / active strategic alternatives process","eventProgression":"reaffirmation of prior rejection with new detail on strategic alternatives","retailFavoriteBoost":true}},"event_type":"m_and_a","event_type_secondary":null,"sentiment":"neutral","material_impact_score":4,"narrative":"Aurora Cannabis' board, on the unanimous recommendation of its Special Committee, again advised shareholders to reject Curaleaf's revised hostile bid for all outstanding ACB shares.\n\nThe board says the revised offer significantly undervalues Aurora, which is debt-free with a strong cash position, and that the cash consideration would effectively be funded by Aurora shareholders' own balance-sheet cash.\n\nAurora's Special Committee is actively exploring strategic alternatives, having signed confidentiality and standstill agreements with multiple interested parties; Curaleaf's bid remains open until December 4, 2026.\n\nShareholders are advised to take no action, as tendering early could undermine the potential for a superior outcome from the strategic review.","key_figures":{"customDimensions":{"bid_status":"revised hostile bid rejected; strategic alternatives process ongoing","bid_expiration":"December 4, 2026"}},"named_entities":{"people":[{"name":"Miguel Martin","role":"Executive Chairman and CEO of Aurora Cannabis"},{"name":"Michelle Lefler","role":"VP, Communications & PR, Aurora Cannabis"}],"products":["Aurora","MedReleaf","Pedanios","IndiMed","San Raf","Whistler Medical Marijuana Corporation"],"companies":[{"name":"Aurora Cannabis Inc.","ticker":"ACB","relationship":"filer / bid target"},{"name":"Curaleaf Holdings, Inc.","ticker":"CURA","relationship":"hostile bidder"},{"name":"Kingsdale Advisors","relationship":"strategic advisor and information agent"},{"name":"ICR, Inc.","relationship":"investor relations"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-14T19:49:17.768Z","global_importance":55,"audience_relevance":60,"importance_components":{"tickerTier":"mid-cap cannabis, well-known retail name","eventGravity":"hostile M&A defense / active strategic alternatives process","eventProgression":"reaffirmation of prior rejection with new detail on strategic alternatives","retailFavoriteBoost":true}},"durationMs":6487,"modelName":"glm-5.3-flashx"}}